NHS cancer waiting times hit 18-month low

The proportion of NHS cancer patients in England waiting more than 62 days for treatment has fallen to its lowest point in a year and a half, according to the latest NHS England performance statistics, offering cautious optimism that targeted investment and operational reforms are beginning to produce measurable results across oncology services.

The figures, published by NHS England, show that the 62-day referral-to-treatment standard — a key benchmark in cancer care — is being met for a greater share of patients than at any point in recent memory, following a sustained period of record-high delays that drew sharp criticism from clinicians, patient groups, and parliamentary health committees alike.

What the Data Show

NHS England's monthly cancer waiting times statistics reveal that the percentage of patients beginning treatment within 62 days of an urgent GP referral has risen notably, reversing a trend that had persisted through several consecutive reporting periods. The 62-day standard requires that 85 per cent of patients receive treatment within that window following an urgent suspected cancer referral.

Key Metrics in Context

While the service has not yet returned to full compliance with the 85 per cent target, the trajectory is broadly positive. The NHS Long Term Plan had established ambitious milestones for cancer care, including a commitment to diagnose 75 per cent of cancers at stage one or two. Recent data suggest that early diagnosis rates are also improving, aided by expanded community diagnostic centres and faster triaging of two-week-wait referrals (Source: NHS England).

Separately, the 28-day Faster Diagnosis Standard — introduced to ensure patients receive a definitive cancer diagnosis or ruling-out within four weeks — is also showing incremental improvement, with performance edging closer to the 75 per cent target set nationally (Source: NHS England).

This progress follows a period of significant strain. Readers following the trajectory of NHS oncology performance will recall that this publication previously reported when NHS Cancer Waiting Times Hit 18-Month High, signalling the depth of the challenge facing commissioners and providers across England.

Drivers Behind the Improvement

Health officials and NHS trust leaders have pointed to a convergence of factors behind the improved performance, cautioning against over-interpretation of a single reporting period while acknowledging that structural changes are taking effect.

Community Diagnostic Centres

A central plank of the government's response to the backlog has been the rollout of community diagnostic centres (CDCs), which are purpose-built or repurposed facilities offering CT scans, MRI imaging, endoscopies, and other tests outside of acute hospital settings. More than 160 CDCs are now operational across England, and NHS England officials said collectively they have delivered millions of additional diagnostic tests, reducing pressure on hospital-based imaging departments and shortening pathways from referral to confirmed diagnosis (Source: NHS England).

Workforce Expansion and Retention

The NHS workforce plan, which sets out ambitions to train tens of thousands of additional clinical staff over the coming decade, includes specific provisions for oncologists, radiologists, and specialist cancer nurses — the professions most acutely under-resourced in recent years. NICE guidance on staffing ratios in oncology has been cited by NHS trust executives as a benchmark against which current recruitment efforts are being measured (Source: NICE).

Additionally, NHS England has invested in 'patient tracking lists' — detailed digital tools that allow cancer pathway coordinators to identify patients at risk of breaching waiting time standards and to proactively intervene, according to NHS operational guidance.

Remaining Challenges and Unmet Targets

Despite the improvement, NHS clinical leaders, patient charities, and independent analysts are united in stressing that the service remains under considerable strain. It is worth noting this positive data point in the context of earlier reports: the period when NHS Cancer Waiting Times Hit Record High left a structural deficit that will take sustained effort to resolve.

Inequalities Across Tumour Types

Performance varies significantly by cancer type. Skin cancer, lower gastrointestinal, and urology pathways have historically experienced the longest waits, and while improvements have been recorded, these areas continue to fall furthest short of national standards. Patients in some regions of England wait considerably longer than those in better-resourced areas, a disparity that NHS commissioners have acknowledged must be addressed through targeted pathway investment (Source: NHS England).

The 62-Week Benchmark

The most clinically concerning metric remains the number of patients waiting beyond 62 weeks — a threshold beyond which evidence suggests outcomes worsen materially. As this publication previously documented in depth, efforts to eliminate ultra-long waits have proven difficult; the moment when NHS cancer waiting times breach 62-week threshold represented a particularly alarming juncture for patient safety advocates and oncology consultants nationwide.

NHS England data show that while the number of patients in this category has fallen from its peak, it remains above pre-pandemic levels, and officials have stated that eliminating waits beyond 62 weeks remains a priority for cancer alliances and integrated care boards (Source: NHS England).

Government and NHS Response

Health ministers have welcomed the data while framing them as evidence that the current funding settlement is beginning to deliver. The NHS Cancer Plan, which outlines a multi-year strategy for improving outcomes, early diagnosis, and treatment capacity, includes commitments to expand radiotherapy infrastructure, accelerate genomic testing pathways, and improve palliative care provision across all regions of England.

NHS England's national cancer director has previously stated that the ambition is not merely to restore pre-pandemic performance but to move the system to a fundamentally higher standard of care, particularly in early diagnosis, where the survival gains are most significant (Source: NHS England).

WHO data consistently show that countries achieving high rates of stage one and stage two cancer diagnoses see substantially better five-year survival rates, a point that underpins the NHS's strategic emphasis on screening programmes and symptomatic referral pathways (Source: WHO).

What This Means for Patients

For patients and members of the public, the improving trajectory represents encouraging news, though clinical experts emphasise that the most effective individual action remains prompt reporting of potential symptoms and engagement with national screening programmes.

Cancer Symptoms That Should Prompt Urgent GP Referral

• Unexplained weight loss over a period of several weeks
• Persistent, unexplained fatigue not attributable to lifestyle or sleep
• A new lump or swelling anywhere on the body that does not resolve
• Persistent cough or hoarseness lasting more than three weeks
• Unexplained changes in bowel or bladder habits
• Blood in urine, stools, or sputum without an obvious cause
• Difficulty swallowing or persistent indigestion
• Unusual skin changes, including new moles or changes to existing ones
• Unexplained pain that is new, persistent, or worsening
• Mouth ulcers or patches that do not heal within three weeks

NICE guidance strongly recommends that patients do not delay seeking a GP appointment if they experience any of the above, as early presentation remains the single most significant modifiable factor in improving cancer outcomes (Source: NICE).

Historical Context and the Road Ahead

The trajectory of NHS cancer waiting times over recent years has been closely documented. The period during which NHS Cancer Waiting Times Hit Five-Year High underlined the systemic nature of the problem, which predated the pandemic and was significantly exacerbated by it.

Analysts from the King's Fund and the Nuffield Trust have consistently noted that improving cancer waiting times requires not only investment in diagnostic and treatment infrastructure, but also workforce stability, effective primary care referral pathways, and public awareness campaigns that encourage earlier symptom presentation. A BMJ editorial published in a recent issue called for renewed focus on reducing socioeconomic inequalities in cancer diagnosis, noting that patients from more deprived communities are disproportionately likely to present at later stages (Source: BMJ).

Looking at the broader picture, the NHS faces a long-term challenge in meeting rising demand as the population ages and cancer incidence increases. NHS modelling suggests that the number of cancer diagnoses in England will rise substantially over the coming two decades, placing sustained pressure on pathways that are only now beginning to recover their footing.

For now, the latest data represent a meaningful, if incomplete, step forward. Whether the improvement is sustained will depend on continued investment, workforce growth, and the operational capacity of cancer alliances and integrated care boards to maintain reform momentum — factors that health policy observers will be watching closely in forthcoming reporting periods.